Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. - Wikidata - wikimedia - TriplyDB

Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.

Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.

http://www.wikidata.org/entity/Q34129599

about

Psychiatric and substance use disorders co-morbidities and hepatitis C: Diagnostic and treatment implications Tangible resources for preparing patients for antiviral therapy for chronic hepatitis C Antidepressant prophylaxis reduces depression risk but does not improve sustained virological response in hepatitis C interferon recipients without depression at baseline: a systematic review and meta-analysis Quinolinic Acid Responses during Interferon-α-Induced Depressive Symptomatology in Patients with Chronic Hepatitis C Infection - A Novel Aspect for Depression and Inflammatory Hypothesis Association of Changes in Mood Status and Psychosocial Well-Being with Depression During Interferon-Based Treatment for Hepatitis C.Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015.Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3.All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C.A Preliminary Study on the Relationship between Platelet Serotonin Transporter Functionality, Depression, and Fatigue in Patients with Untreated Chronic Hepatitis C.Depression and Chronic Liver Diseases: Are There Shared Underlying Mechanisms?Recurrence of depressive disorders after interferon-induced depression.Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.Depression and antiviral response to interferon-based therapy for hepatitis C virus infection Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children Management of Adverse Events During the Treatment of Chronic Hepatitis C Infection.Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: a 16-week prospective study.Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners: the Perseo study An Aggravated Trajectory of Depression and Anxiety Co-morbid with Hepatitis C: A Within-groups Study of 61 Australian Outpatients.Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute?The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D).Short interferon and ribavirin treatment for HCV genotype 2 or 3 infection: NORDynamIC trial and real-life experience.A comparison of modified directly observed therapy to standard care for chronic hepatitis C.Effect of interferon-α on cortical glutamate in patients with hepatitis C: a proton magnetic resonance spectroscopy study.Role of inflammatory cytokines in depression: Focus on interleukin-1β.Paeoniflorin ameliorates interferon-alpha-induced neuroinflammation and depressive-like behaviors in mice.Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future.Psychological, lifestyle and social predictors of hepatitis C treatment response: a systematic review.Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation.Provision of clinical pharmacist services for individuals with chronic hepatitis C viral infection: Joint Opinion of the GI/Liver/Nutrition and Infectious Diseases Practice and Research Networks of the American College of Clinical Pharmacy.Changes in the NMR Metabolic Profile of Live Human Neuron-Like SH-SY5Y Cells Exposed to Interferon-α2.Pathogen-Host Defense in the Evolution of Depression: Insights into Epidemiology, Genetics, Bioregional Differences and Female Preponderance.Depression in HIV and HCV co-infected patients: a systematic review and meta-analysis.Neuropsychiatric side-effects of interferon-alpha treatment: pathophysiology and therapeutic options.Depressive symptoms are frequent among drug users, but not associated with hepatitis C infection.Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C.Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.Clinimetrics and clinical psychometrics: macro- and micro-analysis.Major depression and suicide attempts in patients with liver disease in the United States.Acceptability of psychotherapy, pharmacotherapy, and self-directed therapies in Australians living with chronic hepatitis C.Hepatitis C virus eradication improves immediate and delayed episodic memory in patients treated with interferon and ribavirin.

P2860

Q26798477-EB77CF04-6AC3-46BD-9BF2-F5F6A5EA03EE Q26858962-6C2D2D2D-807D-42CC-B28A-91BF594A35F2 Q26864986-B2194F36-CB08-4D19-88B6-72C7CCC839EA Q28607691-5DDFBDC3-2123-46F1-9E09-2714C067D78A Q30355874-9896A1CD-3DBA-4DAD-A41B-4A71CD3AC8E2 Q31024615-DE03943E-9247-4581-892C-F9A364D1B2AB Q33413296-256BE32C-1204-445E-86C9-5B8AB8743F91 Q33413353-D09099EE-3E79-4D68-8778-4FD9ECD1A81A Q33414941-51DD68AE-7D10-4936-BEB7-4EA80596B139 Q33645706-AA7F6453-23A6-4EB7-8D67-62B014D87936 Q33707679-3E22804A-F6F5-4C56-B7C5-AC8C13F8BB66 Q34143327-D87A7ED5-1024-4A3C-A3CE-679DED9AE454 Q34779005-40C53103-D5BF-4BEF-BA52-A310332DBD11 Q34861058-11AC7550-3367-45BB-8556-9521F3B94919 Q35082620-EBA49F74-4EDA-4BDE-BD42-7683914D50BA Q35535322-5446F3E5-6989-4C6A-8070-A804F3A9C7EF Q35749560-B9462EBD-3F24-401E-95EA-223246A79A90 Q36364055-F83A7E4B-2E9F-405B-9659-679FB42C42A6 Q36418455-A488E889-2196-414B-8EF2-47C6B615D4FF Q36493625-84C3CFBC-4B8B-4317-BAFE-2FB532659383 Q36519135-F4FFBBC4-B51D-4D9C-BBB7-906383736371 Q36997166-8DAAC833-7922-4628-9C39-F07B7A0D4290 Q37136152-F5F76B90-4124-471B-8545-D4B9C13A5B16 Q37593869-B8B6FACA-4546-470E-A896-FB34B0EC6BE1 Q37702695-1E7DC844-AE98-4294-B20E-4288155D5249 Q37846232-199CC286-B90C-4380-A155-08337045ED6F Q38098579-BD182121-224E-4A58-8FD0-6A1073578DA5 Q38245124-EA86F5FC-6C8F-4A35-8FD8-F49603EE700D Q38264060-AF6E1E5F-61CE-405E-A5CC-D714900A8D86 Q38821765-7DBE8FD2-2BE1-430D-8F89-A305B4FE6E88 Q38954644-31772129-BA8B-4836-A99D-A549EF0B5B06 Q39093985-CB96BEF4-3A40-4289-AF4B-8127D79E6138 Q42029245-B0D372BF-375A-4967-9B9A-BC3B51EB88DF Q42210277-684DF035-B6A5-4F31-A08E-909E7D985D55 Q43041286-9375FE49-EF89-44C4-A532-1F706BA47A4B Q43042527-D3F5305B-7441-4EE1-85F7-41E982FD6FC8 Q43794534-6FE4BC70-AC5D-42C9-8C02-40B6F4505091 Q45117603-23588A7A-C0E5-485D-A9BE-FB91C0A9C817 Q45259841-A5B889FC-BA6A-405E-BDFD-C5F93B2A42CE Q45324202-6A19FB70-EC12-445D-9CB0-B14A8DC0D9FE

P2860

Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.

http://www.wikidata.org/entity/Q34129599

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.

@ast

Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.

@en

Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.

@nl

type

label

Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.

@ast

Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.

@en

Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.

@nl

prefLabel

Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.

@ast

Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.

@en

Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C.

@nl

P1433

Q34129599-558A38BB-A291-4257-90B9-C1A49DD4D282

P1476

Q34129599-55DF5C9C-3DA1-4DBD-9A72-21C5D9761C90

P2093

Q34129599-0EED78FB-A344-4007-94D6-AC66B230F6DD

Q34129599-125BEE2D-4355-4769-8A31-F7E49B3A601D

Q34129599-7EB80C31-CF3A-4609-B79F-5CC191A89A31

Q34129599-86D02F0F-A49D-4736-B036-F1F722982C4E

Q34129599-87F52E71-7F45-4C08-8EAF-85CAA77893B9

Q34129599-C4E52061-D5FA-4C87-B5D4-CDCF6D27B872

Q34129599-DE8E9101-4C9B-4F93-AAE7-86C5079D373A

P2860

Q34129599-0CD664DE-DE75-4281-8693-142188918FB6

Q34129599-13AC0443-EB04-4983-B8E8-26515FD7EB38

Q34129599-1AB96BF6-F5D0-4DDB-B41F-4F42E5B70F39

Q34129599-282DEE45-A6BE-4A4A-A697-154E4D429DD5

Q34129599-45659002-53C3-4A39-AF09-E768EE1FD65C

Q34129599-5B746DC7-D740-430D-B45F-1672B0FADB31

Q34129599-5D483120-F5C3-4ECB-B8CA-C348EAC520C3

Q34129599-692BB3BE-3ED7-4CA1-8F5E-3DE83C787165

Q34129599-72EE7116-3416-49A8-8DBF-9F2A1523C288

Q34129599-8CD6125F-946C-4B48-A67E-A6BBC5B4E3D3

P304

Q34129599-E21A6EC1-0951-4CC1-9995-38CDDC1A27D6

P31

Q34129599-517B49F0-A5B5-48E8-9813-86C6B1501341

P356

Q34129599-3A78A298-7803-4CC9-883F-E05B2213F4A4

P407

Q34129599-E79B865F-037C-4CB5-8A49-394B208ACB25

P433

Q34129599-54625F12-A4B5-43B3-9ADB-FE52548189B4

P478

Q34129599-1F7E3759-CDA0-4025-8FA2-85A975B7F450

P50

Q34129599-50684212-B894-4822-82CC-8B2D41A09D22

Q34129599-934E2C7C-13CC-419C-AE6D-DF274CC7D96B

Q34129599-CC4D81BD-DB46-45F0-9AE1-93A161FD6F97

Q34129599-D8BC38AC-4D75-4EEF-B353-9AD0D9852EBF

Q34129599-F4390CBE-9682-4455-85C8-F78859E908AC

P577

Q34129599-252A1EB2-E725-460B-BED2-BD065A137D88

P5875

Q34129599-5066262E-3CCE-4539-95F3-A934D7914314

P698

Q34129599-697CC83C-027D-4D66-9E0E-5AD0F6E040D6

P921

Q34129599-664F1251-80C7-48B2-BD5E-7E0544548148

P356

P1433

P1476

Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C

@en

P2093

Court Pedersen

http://www.w3.org/2001/XMLSchema#string

Gunnar Norkrans

http://www.w3.org/2001/XMLSchema#string

Kristine Mørch

http://www.w3.org/2001/XMLSchema#string

Mads Rauning Buhl

http://www.w3.org/2001/XMLSchema#string

NORDynamIC Group

http://www.w3.org/2001/XMLSchema#string

Nina Langeland

http://www.w3.org/2001/XMLSchema#string

Simon Hjerrild

http://www.w3.org/2001/XMLSchema#string

P2860

An Inventory for Measuring Depression

Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

The hospital anxiety and depression scale

A SELF-RATING DEPRESSION SCALE

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

The sensitivity and specificity of the Major Depression Inventory, using the Present State Examination as the index of diagnostic validity.

The internal and external validity of the Major Depression Inventory in measuring severity of depressive states.

Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection.

P304

430-435

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.23699

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P50

Martti Färkkilä

Peter Leutscher

Kristoffer Hellstrand

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45495279

http://www.w3.org/2001/XMLSchema#string

P698

20683942

http://www.w3.org/2001/XMLSchema#string

P921